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Abstract
Molecular identiﬁcation of Streptococcus pneumoniae serotype 19F is routinely performed by PCR targeting the wzy gene of the capsular
biosynthetic locus. However, 19F isolates with genetic similarity to 19A have been reported in the United States and Brazil. We
screened 78 pneumococcal carriage isolates and found six 19F wzy variants that originated from children in Papua New Guinea and Fiji.
Isolates were characterized using multilocus sequence typing and opsonophagocytic assays. The 19F wzy variants displayed similar
susceptibility to anti-19F IgG antibodies compared to standard 19F isolates. Our ﬁndings indicate that these 19F variants may be more
common than previously believed.
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Introduction
Streptococcus pneumoniae (the pneumococcus) is a major cause
of childhood morbidity and mortality, with the highest burden of
disease occurring in resource-limited countries [1]. Pneumo-
coccal serotyping is important for disease surveillance and
monitoring changes in serotype distributions associated with
pneumococcal conjugate vaccine (PCV) use. The antibody-based
Quellung reaction is the current reference standard, whereas
serotyping by multiplex PCR is successfully used as an alternative
to antibody-based methods in many laboratories worldwide [2].
However, problems differentiating the closely related serotypes
19F and 19A by PCR have been reported [3]. These serotypes
are common in invasive disease, but pneumococcal vaccine
coverage differs: 19F is included in both PCV10 and PCV13,
whereas 19A is included only in PCV13 [4].
In 2009, the United States Centers for Disease Control and
Prevention (CDC) identiﬁed a 19F isolate with genetic similarity
to serotype 19A (multilocus sequence type 3040) and revised
the serotype 19A primers, which target wzy, to avoid false-
positive results [5]. More recently, similar 19F wzy variants
were found in Brazil [6], prompting speculation that these
strains are more common than previously believed.
The objectives of this study were to identify and characterize
19F wzy variant isolates present in nasopharyngeal swabs
collected from young children aged 0 to 24 months in low- and
middle-income countries (as categorized by the World Bank,
http://data.worldbank.org/about/country-and-lending-groups)
and to examine the susceptibility of 19F wzy variants to
antibody-mediated killing.
Methods
A total of 78 pneumococcal carriage isolates were screened
using a PCR designed to target 19F wzy variants (BUGS-19E F:
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TGACAATTCTGGTTGACTTGTTG, R: AGTACGGGTAC-
CAAGGATTCAC). These primers were designed in silico using
publically available 19F, 19A and 19F variant wzy gene sequences
to target regions of sequence divergence and ensure speciﬁcity.
These primers, plus the current CDC 19F and 19A primers,
were validated using a panel of reference pneumococcal isolates
of serotype 19F, 19A and 19F variants that conﬁrmed the
speciﬁcity of each primer pair (data not shown). The 78 isolates
screened included 33 isolates from Kenya, Papua New Guinea
(PNG), South Africa, The Gambia, Fiji and Bangladesh (n = 13, 6,
5, 4, 3 and 2, respectively) previously typed as 19F by Quellung
reaction as part of the PneuCarriage project (Satzke et al., paper
presented at the 9th International Symposium on Pneumococci
and Pneumococcal Diseases, 2014), and an additional 45 isolates
from Fiji collected during pneumococcal vaccine studies and
typed as 19F, 19A or nontypeable by reverse-line blot testing or
Quellung reaction [7]. Informed consent and approval by local
human ethics committees were obtained before sample collec-
tion as part of the original studies.
Results and Discussion
Six isolates (ﬁve from PNG and one from Fiji) were found to be
19F wzy variants. Results for the 78 isolates were 100%
concordant when PCR was performed using the CDC 19Fvar
primers [6], which target a similar region of the wzy gene. These
six isolates were characterized by multilocus sequence typing
(MLST) [8] and sequencing of the 607 bp BUGS-19E PCR
product (partial wzy gene). MLST results are shown in Table 1.
Three of the PNG isolates were the same sequence type (ST)
and the other two were novel STs not previously found in the
MLST database. The Fiji isolate was a novel ST (ST10233) with 5
of 7 alleles identical to ST6904. The six isolates in our study had
identical partial wzy sequences (GenBank accession no.
KR002679). Sequence alignment was performed by ClustalW
[9] to compare this sequence with the wzy sequences from
original ST3040 isolate from CDC [5] and the more recently
identiﬁed wzy 19F variants from Brazil [6]. The isolates from
our study had four single nucleotide variations compared to the
ST3040 wzy sequence, three of which were shared with the
Brazil wzy sequence.
To investigate whether the 19F wzy variants had altered
susceptibility to killing by anti-19F IgG (which could potentially
affect vaccine effectiveness), opsonophagocytic assays (OPAs)
were performed using sera from vaccinated children in Fiji who
participated in a pneumococcal vaccine trial [10]. A reference
19F laboratory strain (SPEC19F), a standard 19F carriage isolate
from Fiji (PMP1113) and two 19F wzy variant isolates (PMP1107
from Fiji and PMP1108 from PNG) were examined in OPAs
using sera from six children (all isolates tested with each sera).
OPA titres were similar for all four isolates: for sera with high
levels of 19F IgG (> 50 μg/mL), the geometric mean was 2435
(95% conﬁdence interval 370, 16 015) for standard 19F isolates
and 2048 (95% conﬁdence interval 832, 5039) for 19F wzy
variants (p 0.46, unpaired t test). For sera with lower levels of
19F IgG, titres were low, and no differences were observed
(data not shown). These results indicate that 19F wzy variants
do not have a different susceptibility to anti-19F IgG–mediated
killing than standard 19F isolates.
19F wzy variants may be more common than previously
believed, especially in certain geographical regions such as Brazil
and Oceania. It is important that appropriate serotyping
methods are used to avoid falsely identifying them as serotype
19A. Data from OPAs suggest that these 19F isolates are ge-
netic variants without functional differences in their capsule.
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